他克莫司与吗替麦考酚酯治疗儿童频复发或激素依赖型肾病综合征的随机临床试验
这项多中心开放标签随机临床试验纳入270例2至18岁频复发或激素依赖型肾病综合征患儿,1:1分配接受他克莫司或吗替麦考酚酯治疗1年。他克莫司组1年无复发生存率显著更高(HR 2.86,95%CI 1.79-4.76,P<.001),年复发率更低(17.78% vs 41.48%),累积激素剂量更少,安全性相似。
要点
- 他克莫司较吗替麦考酚酯显著提高1年无复发生存率(HR 2.86)。
- 他克莫司组年复发率17.78%,低于吗替麦考酚酯组的41.48%。
- 他克莫司组累积激素剂量更低,两组安全性相似。
核心结论
- 在频复发或激素依赖型肾病综合征患儿中,与吗替麦考酚酯相比,1年他克莫司治疗显著延长无复发生存期。
研究设计与样本
- 多中心、开放标签随机临床试验,在中国12个儿童肾脏病中心开展,纳入270例2至18岁频复发或激素依赖型肾病综合征患儿,1:1分配至他克莫司组(n=135)或吗替麦考酚酯组(n=135)。
- 干预为口服他克莫司(0.025-0.050 mg/kg,每日两次)或吗替麦考酚酯(10-15 mg/kg,每日两次)治疗1年,同时联合激素逐渐减量方案。
主要发现
- 在意向性治疗分析中,他克莫司组1年无复发生存率是吗替麦考酚酯组的1.86倍(HR 2.86;95%CI 1.79-4.76;P<.001)。
- 符合方案分析中差异仍显著(HR 2.78;95%CI 1.72-4.55;P<.001)。
- 他克莫司组首次复发时间均值(SD)为323.99(98.33)天,长于吗替麦考酚酯组的263.21(132.84)天。
- 他克莫司组年复发率低于吗替麦考酚酯组(17.78% vs 41.48%)。
- 他克莫司组平均(SD)累积激素剂量更低(0.22 [0.10] mg/kg/day vs 0.34 [0.22] mg/kg/day)。
临床怎么用
- 对于频复发或激素依赖型肾病综合征患儿,可考虑优先选用他克莫司以延长无复发时间并减少激素累积剂量。
- 他克莫司与吗替麦考酚酯安全性相似,选择时需结合患儿个体情况。
局限性
- 本研究为开放标签设计,未设盲法。
- 研究人群仅来自中国12个中心,外推性需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Both tacrolimus (TAC) and mycophenolate mofetil (MMF) are recommended for children with frequently relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS). However, their comparative effectiveness and safety have not been evaluated through randomized clinical trials. OBJECTIVE: To compare the effectiveness and safety of TAC and MMF in children with FRNS or SDNS. DESIGN, SETTING, AND PARTICIPANTS: In this multicenter, open-label randomized clinical trial conducted at 12 pediatric nephrology centers across China, 270 children aged 2 to 18 years with FRNS or SDNS were allocated at a 1:1 ratio to treatment with either TAC or MMF. The study was conducted from November 2019 to July 2023, and data analysis was completed from July 2023 to March 2024. INTERVENTION: Patients received either TAC (0.025-0.050 mg/kg, orally twice daily) or MMF (10-15 mg/kg, orally twice daily) for 1 year, along with a tapering regimen of steroids. MAIN OUTCOMES AND MEASURES: The primary end point was 1-year relapse-free survival. Relapse frequency, cumulative steroid dosage, and safety profiles were also evaluated. RESULTS: A total of 292 patients from 12 care centers were assessed for eligibility, and 270 patients were randomized to receive either TAC (n = 135) or MMF (n = 135). Among 270 patients, median (IQR) age was 6.91 (4.25-9.96) years, and 70 patients (25.9%) were female. Compared with MMF, the 1-year relapse-free survival rate in the TAC group was 1.86-fold higher (hazard ratio [HR], 2.86; 95% CI, 1.79-4.76; P < .001) in the intention-to-treat analysis. This difference was also significant after adjusting for the per-protocol analysis (HR, 2.78; 95% CI, 1.72-4.55; P < .001). The mean (SD) time to first relapse was significantly longer in the TAC group (323.99 [98.33] days) compared to the MMF group (263.21 [132.84] days). Furthermore, the TAC group showed a lower annual relapse rate than the MMF group (17.78% vs 41.48%) and required a significantly lower mean (SD) cumulative steroid dose (0.22 [0.10] mg/kg/day vs 0.34 [0.22] mg/kg/day). The safety profile was similar in both groups. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, compared with MMF, a 1-year course of TAC therapy significantly extended the period of relapse-free survival in children with FRNS or SDNS. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04048161.
引用
- Wang J, Liu F, Yan W, et al. Tacrolimus or Mycophenolate Mofetil for Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome: A Randomized Clinical Trial. JAMA Pediatr. 2025. PMID: 40354041. doi:10.1001/jamapediatrics.2025.0765
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。